Conditions: Hypertriglyceridemia HIV Infection
Keywords: HIV triglycerides fosamprenavir
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 36
Healthy volunteers: no

Brief summary:
In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in fasting triglycerides \< 200 mg /dL while maintaining virologic suppression.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Lovaza intervention 2: fosamprenavir/ritonavir
Intervention descriptions: intervention 1: Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks intervention 2: Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day

Protocol document: